{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T18:57:15Z","timestamp":1788116235992,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K23 HL123601-01"],"award-info":[{"award-number":["K23 HL123601-01"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA06973"],"award-info":[{"award-number":["P30 CA06973"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA225618"],"award-info":[{"award-number":["P01 CA225618"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bbmt.2020.07.037","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T02:40:49Z","timestamp":1597718449000},"page":"2075-2081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide"],"prefix":"10.1016","volume":"26","author":[{"given":"Amy E.","family":"DeZern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Elmariah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Zahurak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Abbas","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lode J.","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Imus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Borrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina D.","family":"Wagner-Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Luznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.07.037_bib0001","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0002","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0003","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0004","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0005","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0006","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","article-title":"Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults","volume":"33","author":"Kasamon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0007","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.bbmt.2018.01.011","article-title":"Shortened-duration tacrolimus after nonmyeloablative, HLA-haploidentical bone marrow transplantation","volume":"24","author":"Kasamon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0008","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/bbmt.2003.50000","article-title":"A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections","volume":"9","author":"Anderson","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0009","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0010","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/bmt.2014.312","article-title":"Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants","volume":"50","author":"Passweg","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0011","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/01.tp.0000203556.06145.5b","article-title":"Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation","volume":"81","author":"Burroughs","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0012","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1586\/17474086.2014.898561","article-title":"Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis","volume":"7","author":"Nakamura","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0013","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbmt.2013.01.016","article-title":"Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies","volume":"19","author":"Gladstone","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0014","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0015","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0016","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0017","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0018","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0019","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","article-title":"Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation","volume":"25","author":"Imus","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0020","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/bloodadvances.2016002766","article-title":"Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide","volume":"1","author":"Kasamon","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0021","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0022","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0023","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood-2003-02-0482","article-title":"HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies","volume":"102","author":"Maris","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0024","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2014.12.007","article-title":"Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults \u2013 a systematic review and meta-analysis","volume":"94","author":"Holtick","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0025","article-title":"Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults","volume":"4","author":"Holtick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0026","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/imt.11.174","article-title":"NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation","volume":"4","author":"Farhan","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0027","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.07.037_bib0028","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:32:32Z","timestamp":1778797952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120304523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1083879120304523"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.037","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}